Sagimet Biosciences Inc Series A (SGMT)

$10.58 +0.15 (1.44%)
Market Cap 339.86M
Revenue (ttm) 0.00
Net Income (ttm) -51.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 980,500
Avg Vol 1,293,980
Day's Range N/A - N/A
Shares Out 32.59M
Stochastic %K 80%
Beta 3.37
Analysts Strong Sell
Price Target $28.50

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 561 8600
Address:
155 Bovet Road, Suite 303, San Mateo, United States
BostonDave
BostonDave Aug. 17 at 8:14 PM
$SGMT Another form 4. Rule 10b5-1 trading plan adopted on August 21, 2025. https://ir.sagimet.com/node/8711/html
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 7:53 PM
$SGMT the XBI had a decent day-it looks likes some profit takers stepped in and scalped it at it's high today. I hope this is not the case already.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 3:53 PM
$SGMT Why is this taking months to dose the 1st patient? I would have expected that they would have all this buttoned up by now and ready to launch at the sites.
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 3:21 PM
$SGMT Happel said the company has an open investigational new drug application and has received a "study may proceed" determination from the FDA. Sagimet expects to dose its first patient within the next couple of months, with last-patient, last-dose anticipated around this time next year and topline data shortly afterward.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 3:18 PM
$SGMT this is why...funny money coming https://finance.yahoo.com/healthcare/articles/sagimet-biosciences-eyes-u-phase-080155488.html
0 · Reply
shibadad
shibadad Aug. 17 at 2:47 PM
$SGMT With the inclusion into the Russell index funds and the secondary placed with institutions, the retail float has shrunken dramatically. 85% of the 61M shares outstanding are with institutions leaving only about 9M in retail float. The last report showed 11M shares short. If that's all retail, then they could be scrambling here.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 2:46 PM
$SGMT I think we should see some short covering right about now.
0 · Reply
Valueforall
Valueforall Aug. 17 at 2:27 PM
$SGMT 11 handle here nice to see! Appreciate all the research from the OGs here @valueforme 🫵👍 et all!
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 14 at 10:03 PM
$SGMT I'm really liking our $12-13 zone now. We will get some monolpoly money from China soon. They can have a big pizza party with that. I just ask that you find a home for defini and not leave this to the graveyard.
0 · Reply
shibadad
shibadad Aug. 14 at 9:22 PM
$SGMT In addition to previously reported positions, these are all new positions reported in Q2. Props to SGMT management and underwriters for getting their story out. BVF 2.5M shares. Caligan 2.5M shares. Saturn V 1.5M shares. Ameriprise 581k shares. Vestel 535k shares. Northern Trust 468k shares. Boothbay 464k shares. Northern Trust 468k shares. Farallon 415k shares . Atom Investors 348k shares Rock Springs 250k shares. Bank of NY Mellon 200k shares. Driehaus Capital 167k shares Nuveen 141k shares Propel Bio 126k shares
3 · Reply
Latest News on SGMT
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 17, 2026, 4:28 PM EDT - 1 day ago

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences price target raised to $56 from $49 at Canaccord

2026-08-17T10:01:51.000Z - 2 days ago

Sagimet Biosciences price target raised to $56 from $49 at Canaccord

Sagimet Biosciences price target raised to $29 from $12 at Citizens

2026-08-16T13:52:58.000Z - 2 days ago

Sagimet Biosciences price target raised to $29 from $12 at Citizens

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Sagimet Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 1:00 PM EDT - 7 days ago

Sagimet Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference

Sagimet Biosciences Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Sagimet Biosciences Quarterly report: Q2 2026

Sagimet Biosciences Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Sagimet Biosciences Earnings release: Q2 2026

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Aug 4, 2026, 7:00 AM EDT - 15 days ago

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Sagimet Biosciences joins Russell 3000, Russell 2000 Indexes

2026-06-29T11:30:24.000Z - 7 weeks ago

Sagimet Biosciences joins Russell 3000, Russell 2000 Indexes

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

Jun 29, 2026, 7:00 AM EDT - 7 weeks ago

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 22, 2026, 8:49 PM EDT - 2 months ago

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

May 27, 2026, 7:00 AM EDT - 3 months ago

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

Sagimet Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 2:00 PM EDT - 3 months ago

Sagimet Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

2026-05-19T09:40:08.000Z - 3 months ago

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

Sagimet Biosciences price target lowered to $28 from $37 at Clear Street

2026-05-14T01:35:51.000Z - 3 months ago

Sagimet Biosciences price target lowered to $28 from $37 at Clear Street

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 13, 2026, 7:00 AM EDT - 3 months ago

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)

2026-05-12T11:45:46.000Z - 3 months ago

Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 12, 2026, 7:30 AM EDT - 3 months ago

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Sagimet Biosciences Quarterly report: Q1 2026

Sagimet Biosciences Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Sagimet Biosciences Earnings release: Q1 2026

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

May 11, 2026, 7:00 AM EDT - 3 months ago

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences price target raised to $49 from $28 at Canaccord

2026-05-04T11:08:03.000Z - 3 months ago

Sagimet Biosciences price target raised to $49 from $28 at Canaccord

Sagimet Biosciences price target raised to $33 from $28 at Oppenheimer

2026-05-01T12:30:43.000Z - 3 months ago

Sagimet Biosciences price target raised to $33 from $28 at Oppenheimer

Sagimet Biosciences Transcript: Status update

Apr 30, 2026, 2:00 PM EDT - 3 months ago

Sagimet Biosciences Transcript: Status update

Sagimet Biosciences Slides: Status update

Apr 30, 2026, 2:00 PM EDT - 3 months ago

Sagimet Biosciences Slides: Status update

Sagimet Biosciences management to meet virtually with Clear Street

2026-04-30T16:53:53.000Z - 3 months ago

Sagimet Biosciences management to meet virtually with Clear Street

Sagimet Biosciences price target lowered to $25 from $27 at Guggenheim

2026-04-29T13:09:12.000Z - 4 months ago

Sagimet Biosciences price target lowered to $25 from $27 at Guggenheim

3 Penny Stocks to Watch Now, 4/28/26

2026-04-28T18:07:00.000Z - 4 months ago

3 Penny Stocks to Watch Now, 4/28/26

HTCO YAAS

Sagimet Biosciences holds a conference call

2026-04-28T17:15:16.000Z - 4 months ago

Sagimet Biosciences holds a conference call

TD Cowen establishes $21 price target for Sagamet Bioscinces

2026-04-28T12:19:03.000Z - 4 months ago

TD Cowen establishes $21 price target for Sagamet Bioscinces

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Apr 27, 2026, 7:15 AM EDT - 4 months ago

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Sagimet Biosciences Provides Strategic and Corporate Updates

Sagimet Biosciences Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Sagimet Biosciences Proxy statement: Proxy filing

Sagimet Biosciences appoints Grauer as Chief Medical Officer

2026-04-20T11:37:22.000Z - 4 months ago

Sagimet Biosciences appoints Grauer as Chief Medical Officer

OMER

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Apr 20, 2026, 7:00 AM EDT - 4 months ago

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences initiated with a Buy at Rodman & Renshaw

2026-03-26T11:46:26.000Z - 5 months ago

Sagimet Biosciences initiated with a Buy at Rodman & Renshaw

Sagimet Biosciences reports Q4 EPS (29c), consensus (43c)

2026-03-11T11:37:39.000Z - 5 months ago

Sagimet Biosciences reports Q4 EPS (29c), consensus (43c)

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Mar 11, 2026, 7:30 AM EDT - 5 months ago

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Earnings release: Q4 2025

Mar 11, 2026, 7:00 AM EDT - 5 months ago

Sagimet Biosciences Earnings release: Q4 2025

Sagimet Biosciences Annual report: Q4 2025

Mar 11, 2026, 7:00 AM EDT - 5 months ago

Sagimet Biosciences Annual report: Q4 2025

Sagimet Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:00 PM EDT - 5 months ago

Sagimet Biosciences Transcript: Leerink Global Healthcare Conference 2026

Sagimet Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:10 PM EST - 6 months ago

Sagimet Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Sagimet Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 11:20 AM EST - 6 months ago

Sagimet Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Feb 25, 2026, 7:00 AM EST - 6 months ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Sagimet Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 10:00 AM EST - 6 months ago

Sagimet Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Feb 5, 2026, 7:00 AM EST - 6 months ago

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Sagimet Biosciences initiated with a Buy at Guggenheim

2026-02-03T12:21:07.000Z - 7 months ago

Sagimet Biosciences initiated with a Buy at Guggenheim

Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Feb 2, 2026, 7:00 AM EST - 7 months ago

Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Jan 29, 2026, 6:00 AM EST - 7 months ago

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Jan 27, 2026, 3:00 AM EST - 7 months ago

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Jan 8, 2026, 7:00 AM EST - 7 months ago

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Dec 18, 2025, 7:00 AM EST - 8 months ago

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

Dec 10, 2025, 7:03 AM EST - 9 months ago

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Dec 10, 2025, 4:15 AM EST - 9 months ago

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 9, 2025, 4:05 PM EST - 9 months ago

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 12:55 PM EST - 9 months ago

Sagimet Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Nov 20, 2025, 7:00 AM EST - 9 months ago

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Sagimet Biosciences Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Sagimet Biosciences Earnings release: Q3 2025

Sagimet Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Sagimet Biosciences Quarterly report: Q3 2025

Sagimet Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 11:30 AM EST - 10 months ago

Sagimet Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Oct 24, 2025, 7:00 AM EDT - 10 months ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Sagimet Biosciences Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 21, 2025, 7:00 AM EDT - 10 months ago

Sagimet Biosciences Transcript: H.C. Wainwright Liver Disease Virtual Conference

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Oct 14, 2025, 6:00 AM EDT - 11 months ago

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Oct 7, 2025, 7:00 AM EDT - 11 months ago

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sep 17, 2025, 7:00 AM EDT - 1 year ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sagimet Biosciences Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:35 PM EDT - 1 year ago

Sagimet Biosciences Transcript: Cantor Global Healthcare Conference 2025

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 13, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q2 2025

Sagimet Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Quarterly report: Q2 2025

Sagimet Biosciences Slides: Investor Presentation

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Slides: Investor Presentation

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Sagimet Biosciences Transcript: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Transcript: KOL Event

Sagimet Biosciences Press release: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Press release: KOL Event

Sagimet Biosciences Slides: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Slides: KOL Event

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Sagimet Biosciences Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Slides: Corporate Presentation

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Jun 4, 2025, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Sagimet Biosciences Transcript: KOL Event

May 29, 2025, 1:00 PM EDT - 1 year ago

Sagimet Biosciences Transcript: KOL Event

Sagimet Biosciences Slides: KOL Event

May 29, 2025, 1:00 PM EDT - 1 year ago

Sagimet Biosciences Slides: KOL Event

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 22, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

Sagimet Biosciences Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q1 2025

Sagimet Biosciences Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Quarterly report: Q1 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 6:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Proxy statement: Proxy Filing

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Earnings release: Q4 2024

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q4 2024

Sagimet Biosciences Annual report: Q4 2024

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Annual report: Q4 2024

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Sagimet Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Sagimet Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Sagimet Biosciences Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences Earnings release: Q3 2024

Sagimet Biosciences Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences Quarterly report: Q3 2024

Sagimet Biosciences Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 8:00 PM EST - 1 year ago

Sagimet Biosciences Transcript: UBS Global Healthcare Conference 2024

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Nov 12, 2024, 6:30 AM EST - 1 year ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 11, 2024, 7:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Biosciences Transcript: 8th Annual MASH Investor Conference

Oct 7, 2024, 2:30 PM EDT - 2 years ago

Sagimet Biosciences Transcript: 8th Annual MASH Investor Conference

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 7:00 AM EDT - 2 years ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2024, 12:05 AM EDT - 2 years ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 9:10 AM EDT - 2 years ago

Sagimet Biosciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sep 12, 2024, 7:30 AM EDT - 2 years ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 11:00 AM EDT - 2 years ago

Sagimet Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sagimet Biosciences Registration statement: Registration Filing

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Registration statement: Registration Filing

Sagimet Biosciences Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Quarterly report: Q2 2024

Sagimet Biosciences Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Earnings release: Q2 2024

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Aug 1, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences Transcript: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Study Update

Sagimet Biosciences Press release: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Press release: Study Update

Sagimet Biosciences Slides: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Slides: Study Update

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Jun 6, 2024, 5:00 AM EDT - 2 years ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences Transcript: Investor & Analyst Day 2024

May 23, 2024, 1:00 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Investor & Analyst Day 2024

Sagimet Biosciences Slides: FY 2024

May 23, 2024, 1:00 PM EDT - 2 years ago

Sagimet Biosciences Slides: FY 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 16, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

BostonDave
BostonDave Aug. 17 at 8:14 PM
$SGMT Another form 4. Rule 10b5-1 trading plan adopted on August 21, 2025. https://ir.sagimet.com/node/8711/html
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 7:53 PM
$SGMT the XBI had a decent day-it looks likes some profit takers stepped in and scalped it at it's high today. I hope this is not the case already.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 3:53 PM
$SGMT Why is this taking months to dose the 1st patient? I would have expected that they would have all this buttoned up by now and ready to launch at the sites.
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 3:21 PM
$SGMT Happel said the company has an open investigational new drug application and has received a "study may proceed" determination from the FDA. Sagimet expects to dose its first patient within the next couple of months, with last-patient, last-dose anticipated around this time next year and topline data shortly afterward.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 3:18 PM
$SGMT this is why...funny money coming https://finance.yahoo.com/healthcare/articles/sagimet-biosciences-eyes-u-phase-080155488.html
0 · Reply
shibadad
shibadad Aug. 17 at 2:47 PM
$SGMT With the inclusion into the Russell index funds and the secondary placed with institutions, the retail float has shrunken dramatically. 85% of the 61M shares outstanding are with institutions leaving only about 9M in retail float. The last report showed 11M shares short. If that's all retail, then they could be scrambling here.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 17 at 2:46 PM
$SGMT I think we should see some short covering right about now.
0 · Reply
Valueforall
Valueforall Aug. 17 at 2:27 PM
$SGMT 11 handle here nice to see! Appreciate all the research from the OGs here @valueforme 🫵👍 et all!
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 14 at 10:03 PM
$SGMT I'm really liking our $12-13 zone now. We will get some monolpoly money from China soon. They can have a big pizza party with that. I just ask that you find a home for defini and not leave this to the graveyard.
0 · Reply
shibadad
shibadad Aug. 14 at 9:22 PM
$SGMT In addition to previously reported positions, these are all new positions reported in Q2. Props to SGMT management and underwriters for getting their story out. BVF 2.5M shares. Caligan 2.5M shares. Saturn V 1.5M shares. Ameriprise 581k shares. Vestel 535k shares. Northern Trust 468k shares. Boothbay 464k shares. Northern Trust 468k shares. Farallon 415k shares . Atom Investors 348k shares Rock Springs 250k shares. Bank of NY Mellon 200k shares. Driehaus Capital 167k shares Nuveen 141k shares Propel Bio 126k shares
3 · Reply
BostonDave
BostonDave Aug. 14 at 8:46 PM
$SGMT Kemble selling a bunch of stock. https://ir.sagimet.com/sec-filings/sec-filing/144/0001950047-26-008152
3 · Reply
Valueforall
Valueforall Aug. 14 at 8:11 PM
$SGMT The validation that institutions are adding to this microcap and the price validation too lets you know that ultimately, with turbulence, this goes higher. This thing is either junk or worth way more and the probability of way more just rose exponentially the past few weeks.
0 · Reply
Geohotventures
Geohotventures Aug. 14 at 8:03 PM
$SGMT nice close 😎
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 14 at 7:53 PM
$SGMT NICE DAY!
1 · Reply
shibadad
shibadad Aug. 14 at 5:49 PM
$SGMT The 52 week high wasn't much resistance. If we close here or better we may never see single digits again.
1 · Reply
vatexas
vatexas Aug. 14 at 5:47 PM
$SGMT welcome 10's
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 14 at 5:44 PM
$SGMT we printed it-52 week high...
0 · Reply
Valueforall
Valueforall Aug. 14 at 4:19 PM
$SGMT been here for a while. This is getting interesting now. I have traded this from $6-8. Now just gonna hold tight so I don’t regret yet another ‘sold too early’
3 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 14 at 3:20 PM
$SGMT one of the few green stocks today...
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 14 at 1:51 PM
$SGMT some really nice additions in here with some good volume: Farallon
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 14 at 1:38 PM
$SGMT
0 · Reply
shibadad
shibadad Aug. 14 at 12:15 PM
$SGMT Balyasny Asset Management reported 3.6M shares in Q2 which is a new position. Affinity reported 2.5M shares in Q2 which is up 1.6M shares. Northern Trust reported 468k shares in Q2 which is up 412k shares. Marshall Wace sold its entire position of 966k shares.
0 · Reply